Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Mostra altre versioni (1)

Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, MR, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S, Harris, A, Bottini, A, Berruti, A, Generali, D
Natura:	Journal article
Lingua:	English
Pubblicazione:	2013

Documenti analoghi

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
di: Allevi, G, et al.
Pubblicazione: (2013)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
di: Generali, D, et al.
Pubblicazione: (2009)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
di: Generali, D, et al.
Pubblicazione: (2008)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
di: Generali, D, et al.
Pubblicazione: (2011)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
di: Fox, S, et al.
Pubblicazione: (2006)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
di: Andreis, D, et al.
Pubblicazione: (2016)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
di: A Ianza, et al.
Pubblicazione: (2020-06-01)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
di: Foroni, C, et al.
Pubblicazione: (2009)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
di: Fox, S, et al.
Pubblicazione: (2011)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
di: Mele, T, et al.
Pubblicazione: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
di: Mele, T, et al.
Pubblicazione: (2010)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
di: Fox, S, et al.
Pubblicazione: (2011)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
di: Generali, D, et al.
Pubblicazione: (2008)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
di: Generali, D, et al.
Pubblicazione: (2009)

Triple negative breast cancers have a reduced expression of DNA repair genes.
di: Enilze Ribeiro, et al.
Pubblicazione: (2013-01-01)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
di: Generali, D, et al.
Pubblicazione: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
di: Generali, D, et al.
Pubblicazione: (2007)

Oestrogen and progesterone signaling in endometrial receptivity
di: Li Gaizhen, et al.
Pubblicazione: (2022-12-01)

The role of oestrogen and progesterone receptors in gigantomastia
di: Anna Kasielska-Trojan, et al.
Pubblicazione: (2019-09-01)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
di: Generali, D, et al.
Pubblicazione: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
di: Generali, D, et al.
Pubblicazione: (2006)

Expression of genes involved in DNA repair and cell cycle checkpoint pathways in Triple Negative compared to Luminal A Breast Cancer: a molecular characterization
di: Ganzinelli Monica, et al.
Pubblicazione: (2012-04-01)

Activation function 1 of progesterone receptor is required for progesterone antagonism of oestrogen action in the uterus
di: Lee, Shi Hao, et al.
Pubblicazione: (2023)

Activation function 1 of progesterone receptor is required for progesterone antagonism of oestrogen action in the uterus
di: Shi Hao Lee, et al.
Pubblicazione: (2022-10-01)

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
di: Gretchen E Glaser, et al.
Pubblicazione: (2020-10-01)

Author Correction: Activation function 1 of progesterone receptor is required for progesterone antagonism of oestrogen action in the uterus
di: Shi Hao Lee, et al.
Pubblicazione: (2023-02-01)

Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women.
di: Key, T
Pubblicazione: (2011)

Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women
di: Key, T
Pubblicazione: (2011)

Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day
di: Rongju Liu, et al.
Pubblicazione: (2022-07-01)

Oestrogen and progesterone receptors in the uterine wall of bitches with cystic endometrial hyperplasia/pyometra
di: Dhaliwal, G. K., et al.
Pubblicazione: (1999)

Expression of oestrogen and progesterone receptor and intermediate filament proteins in the oviduct of mares with endometrosis
di: Magdalena Profaska, et al.
Pubblicazione: (2023-12-01)

Synergistic activity of letrozole and sorafenib on breast cancer cells.
di: Bonelli, M, et al.
Pubblicazione: (2010)

Are oral oestrogens effective in preventing urinary tract infection in postmenopausal woman
di: Viviana Castro, et al.
Pubblicazione: (2020-06-01)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
di: Generali, D, et al.
Pubblicazione: (2006)

Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review
di: Djordje Marina, et al.
Pubblicazione: (2023-01-01)

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
di: Cavazzoni, A, et al.
Pubblicazione: (2012)

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
di: Cavazzoni, A, et al.
Pubblicazione: (2012)

Enhanced anti-cancer effects of oestrogen and progesterone co-therapy against colorectal cancer in males
di: Amani A. Mahbub, et al.
Pubblicazione: (2022-10-01)

Relations between breast cancer risk and endogenous sex hormones (oestrogen, androgens, progesterone)
di: Key, T
Pubblicazione: (2003)

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
di: Bastert Gunther, et al.
Pubblicazione: (2008-02-01)